(4 intermediate revisions by 3 users not shown) | |||
Line 272: | Line 272: | ||
<li class="navbar-model"><a href="https://2018.igem.org/Team:UI_Indonesia/Model">Model</a></li> | <li class="navbar-model"><a href="https://2018.igem.org/Team:UI_Indonesia/Model">Model</a></li> | ||
<li class="dropdown navbar-humanpractice"> | <li class="dropdown navbar-humanpractice"> | ||
− | <a href="https://2018.igem.org/Team:UI_Indonesia/ | + | <a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Human Practices<span class="caret"></span></a> |
<ul class="dropdown-menu"> | <ul class="dropdown-menu"> | ||
<li><a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Integrated Human Practice</a></li> | <li><a href="https://2018.igem.org/Team:UI_Indonesia/Human_Practices">Integrated Human Practice</a></li> | ||
Line 309: | Line 309: | ||
<br> | <br> | ||
− | <h5> One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in | + | <h5> One of our part which raised concern about security is the DiphTox part. The details regarding this part is discussed in <a href ="http://parts.igem.org/Part:BBa_K2607000" style="color:blue">http://parts.igem.org/Part:BBa_K2607000</a> Regarding safety issues, one of the main purposes of the creation of this part is to eliminate the toxic domain of the protein, leaving only the binding domain to be used as test device for HB-EGF/Tar chimeric receptor. In managing the data, our laboratory had applied several safeguards, such as restricted informational access or password-locked computer. We have also discussed this matter with our PI, dr. Budiman Bela, and also with the Lab Biosafety Officer, Mrs. Aroem Naroeni, which also shared the safety aspects of our laboratory.</h5> |
<br> | <br> |
Latest revision as of 03:42, 18 October 2018
SAFETY AND SECURITY ASPECTS